145 related articles for article (PubMed ID: 1869644)
1. Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression.
Buechner SA
J Am Acad Dermatol; 1991 May; 24(5 Pt 1):731-4. PubMed ID: 1869644
[TBL] [Abstract][Full Text] [Related]
2. Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2-interferon.
Mozzanica N; Cattaneo A; Boneschi V; Brambilla L; Melotti E; Finzi AF
Arch Dermatol Res; 1990; 282(5):311-7. PubMed ID: 2221983
[TBL] [Abstract][Full Text] [Related]
3. The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas.
Edwards L; Tucker SB; Perednia D; Smiles KA; Taylor EL; Tanner DJ; Peets E
Arch Dermatol; 1990 Aug; 126(8):1029-32. PubMed ID: 2383027
[TBL] [Abstract][Full Text] [Related]
4. Intralesional interferon therapy for basal cell carcinoma.
Cornell RC; Greenway HT; Tucker SB; Edwards L; Ashworth S; Vance JC; Tanner DJ; Taylor EL; Smiles KA; Peets EA
J Am Acad Dermatol; 1990 Oct; 23(4 Pt 1):694-700. PubMed ID: 2229497
[TBL] [Abstract][Full Text] [Related]
5. Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery.
Stenquist B; Wennberg AM; Gisslén H; Larkö O
J Am Acad Dermatol; 1992 Jul; 27(1):65-9. PubMed ID: 1619079
[TBL] [Abstract][Full Text] [Related]
6. Treatment of basal cell carcinoma with intralesional interferon alpha: a case report and literature review.
McDonald RR; Georgouras K
Australas J Dermatol; 1992; 33(2):81-6. PubMed ID: 1294057
[TBL] [Abstract][Full Text] [Related]
7. Intralesional interferon-alpha 2b treatment of basal cell carcinoma.
Thestrup-Pedersen K; Jacobsen IE; Frentz G
Acta Derm Venereol; 1990; 70(6):512-4. PubMed ID: 1981427
[TBL] [Abstract][Full Text] [Related]
8. Treatment of basal cell carcinoma with intralesional interferon.
Vinciullo C
Australas J Dermatol; 1993; 34(1):36. PubMed ID: 8240187
[No Abstract] [Full Text] [Related]
9. Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma.
Chimenti S; Peris K; Di Cristofaro S; Fargnoli MC; Torlone G
Dermatology; 1995; 190(3):214-7. PubMed ID: 7599384
[TBL] [Abstract][Full Text] [Related]
10. Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy.
Edwards L; Berman B; Rapini RP; Whiting DA; Tyring S; Greenway HT; Eyre SP; Tanner DJ; Taylor EL; Peets E
Arch Dermatol; 1992 Nov; 128(11):1486-9. PubMed ID: 1444502
[TBL] [Abstract][Full Text] [Related]
11. Expression of human lymphocyte antigen (HLA)-DR on tumor cells in basal cell carcinoma.
Kohchiyama A; Oka D; Ueki H
J Am Acad Dermatol; 1987 Apr; 16(4):833-8. PubMed ID: 2952686
[TBL] [Abstract][Full Text] [Related]
12. Regional and intralesional treatment of invasive basal cell carcinoma with interferon alfa-n2b.
DiLorenzo PA; Goodman N; Lansville F; Markel W
J Am Acad Dermatol; 1994 Jul; 31(1):109-11. PubMed ID: 8021351
[No Abstract] [Full Text] [Related]
13. Treatment of basal cell carcinoma of the nasal pyramid with intralesional interferon alfa-2b.
Fernández-Vozmediano JM; Armario-Hita JC
J Drugs Dermatol; 2010 Apr; 9(4):381-4. PubMed ID: 20514797
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma.
Alpsoy E; Yilmaz E; Başaran E; Yazar S
J Dermatol; 1996 Jun; 23(6):394-6. PubMed ID: 8708151
[TBL] [Abstract][Full Text] [Related]
15. Basal cell carcinoma treated with interferon.
Ikić D; Padovan I; Pipić N; Knezević M; Djaković N; Rode B; Kosutić I; Belicza M
Int J Dermatol; 1991 Oct; 30(10):734-7. PubMed ID: 1955231
[TBL] [Abstract][Full Text] [Related]
16. Consideration of the cost of interferon alfa-2b in the treatment of basal cell carcinoma.
Shiell A
Australas J Dermatol; 1994; 35(2):71-5. PubMed ID: 7702490
[TBL] [Abstract][Full Text] [Related]
17. Intralesional interferon therapy for basal cell carcinoma.
Epstein E
J Am Acad Dermatol; 1992 Jan; 26(1):142-3. PubMed ID: 1732331
[No Abstract] [Full Text] [Related]
18. An absence of human leukocyte antigen-DR and a decreased expression of beta 2-microglobulin on tumor cells of basal cell carcinoma: no influence on the peritumoral immune infiltrate.
Habets JM; Tank B; Vuzevski VD; Stolz E; van Joost T
J Am Acad Dermatol; 1989 Jan; 20(1):47-52. PubMed ID: 2521495
[TBL] [Abstract][Full Text] [Related]
19. Intralesional alfa-2a interferon therapy for basal cell carcinoma.
Doğan B; Harmanyeri Y; Baloğlu H; Oztek I
Cancer Lett; 1995 May; 91(2):215-9. PubMed ID: 7767912
[TBL] [Abstract][Full Text] [Related]
20. Treatment of basal cell carcinoma with intralesional interferon alpha-2b.
Healsmith MF; Berth-Jones J; Fletcher A; Graham-Brown RA
J R Soc Med; 1991 Sep; 84(9):524-6. PubMed ID: 1941852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
